Ran Nussbaum - 25 Mar 2021 Form 4 Insider Report for UroGen Pharma Ltd. (URGN)

Role
Director
Signature
/s/ Jason Smith, Attorney-in-Fact
Issuer symbol
URGN
Transactions as of
25 Mar 2021
Net transactions value
+$11,055
Form type
4
Filing time
09 Jun 2021, 13:42:26 UTC
Previous filing
30 Nov 2022
Next filing
17 May 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction URGN Ordinary Shares Options Exercise $11,055 +2,211 +0.15% $5.00* 1,433,928 25 Mar 2021 Managing Partner of entities affiliated with Pontifax Management III G.P.

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction URGN Stock Option (right to buy) Options Exercise $0 -2,211 -100% $0.000000* 0 25 Mar 2021 Common Stock 2,211 $5.00 by Pontifax (Israel) III Limited Partnership
transaction URGN Stock Option (right to buy) Award $0 +6,817 $0.000000 6,817 07 Jun 2021 Common Stock 6,817 $17.89 by Pontifax (Israel) III Limited Partnership F1
transaction URGN Stock Option (right to buy) Award $0 +3,183 $0.000000 3,183 07 Jun 2021 Common Stock 3,183 $17.89 By Pontifax Cayman III Limited Partnership F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying the stock option will vest in equal quarterly installments over a period of one year.